Lindbrook Capital’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Lindbrook Capital’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14	Closed	-$2K	–	1974
2020 Q4	$2K	Buy	+14	New	+$1.24K	﹤0.01%	1552
2020 Q3	–	Sell	-21	Closed	-$1K	–	1904
2020 Q2	$1K	Hold	21	–	–	﹤0.01%	1689
2020 Q1	$1K	Buy	+21	New	+$1.07K	﹤0.01%	1650
2019 Q1	–	Sell	-1,500	Closed	-$20K	–	1543
2018 Q4	$20K	Buy	+1,500	New	+$18.9K	0.01%	624

Lindbrook Capital's EIDX Position: Q1 2021 in Review

Lindbrook Capital sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 14 shares — an estimated $2K sold.

Lindbrook Capital first reported a position in EIDX in Q4 2018 and held it in 4 quarters. The position peaked at $20K in Q4 2018. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Lindbrook Capital reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Lindbrook Capital sold 14 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2K.
Lindbrook Capital first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
Lindbrook Capital's Eidos Therapeutics, Inc. Common Stock position peaked at $20K in Q4 2018.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Lindbrook Capital's 13F filing for Q1 2021, filed 28 Apr 2021.